Your Top 100 most-cited badge
A badge for your website, a sentence for your CV, and a permanent page where anyone can check the rank.
The article
854O INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI)
Jérôme Fayette, Lisa Francesca Licitra, Kevin Joseph Harrington, Robert I. Haddad, Lillian L. Siu, Yi‐Chun Liu and 14 more
- Rank
- 95 of 3,639
- Percentile
- top 2.7%
- Where
- Annals of Oncology, 2023
- Citations
- 32
From the 2023 list, OpenAlex counts as of 2026-10-29.
Prefer not to be listed? The same link lets you withhold your name on every list; the article stays, your name does not. Questions: team@avidnote.com.